BIOTECHNOLOGY · REGULATION CROWDFUNDING
A preclinical-stage biotechnology company developing BT-1501, an oral investigational therapy designed for APC-mutant colorectal cancer — a mutation commonly found in ~80% of CRC patients. Backed by $17 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and support/investment from the American Cancer Society, Barricade is preparing for first-in-human studies.
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
